CSS Expands Capability in Specialist Manufacturing

December 7, 2004

CSS Expands Capability in Specialist Manufacturing

CSS – one of Europe’s leading providers of Chemistry and Analytical Services – announced today (Tuesday, 7th December 2004) the significant augmentation of its specialist units: Peptides, Oligonucleotides and Proteins and Potent Manufacturing.

Peptides, Oligonucleotides and Proteins

Following successful integration of the peptide and protein business of Albachem within CSS, the company is aiming to accelerate the pace of scientific discovery and development of the next generation of drugs.

Pharmaceutical and Biotechnology companies already benefit from the CSS POP proprietary synthesis and purification techniques of Professor Ramage. These allow easy access to chemically synthesized long proteins (up to 170 amino acids) with all the advantages of speed and purity, only previously possible with much smaller peptides. A major consequence of this integration is the offering of small-scale cGMP manufacture of peptides, oligonucleotides and proteins.

Potent Manufacturing

CSS also announced expansion of its potent and cytotoxic manufacturing and micronisation capabilities following successful commissioning of and production from new facilities in Northern Ireland.

Production of Highly Active Pharmaceutical Ingredients (HAPI), cytotoxics and cytotoxic conjugates is now offered through these exciting developments.

David Moody, VP Commercial Operations, comments:

“This is a another exciting development for CSS, with the technical synergies between the areas providing further benefits to our clients. It strengthens the company’s position in the global biopharmaceutical market and highlights the focus we place on innovation, our commitment to developing our business and to offering an unrivalled service to clients.”

CSS provides organic chemistry expertise; process development, manufacturing and technology transfer capabilities. It is an affiliate company of the Almac Sciences Group, which provides pharmaceutical services across drug discovery, manufacture of API, clinical trials and drug product manufacture. Its operations are based throughout the UK and USA. Any interested parties should contact:

Denis Geffroy (POP) on +44(0)28 38332200 or e-mail [email protected]

Rosaleen McGuckin (Potents) on +44(0)28 38332200 or e-mail [email protected]

All media enquiries:

Darlene McCormick Life COMMUNICATIONS on +44 2890 248805


Back to news